The European Commission (EC) has approved Blenrep (belantamab mafodotin), a first-in-class therapy developed by GlaxoSmithKline (GSK) for the treatment of multiple myeloma. The approval covers Blenrep as a monotherapy — that is, without other treatments — in adults who have been treated with at least four prior therapies, have demonstrated disease progression on the last therapy, and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory treatment, and an anti-CD38 monoclonal antibody. Refractory…
You must be logged in to read/download the full post.
The post First-in-class Blenrep Approved by European Commission for Myeloma appeared first on BioNewsFeeds.